
    
      A randomized control trial comparing oral THU-decitabine to nicotinamide (1:1 randomization),
      and then comparing the effects of the combination of nicotinamide with THU-decitabine vs
      either treatment alone. Treatment with each agent alone is for 12 weeks followed by the
      combination for a further 12 weeks. Patients have the option to enter an extension phase of
      combination treatment for an additional 24 weeks (total of 48 weeks)
    
  